Allergan CEO Saunders to oversee 'Pfizergan' commercial ops; Novartis picks up 2 Cosentyx nods in Europe;

> Allergan ($AGN) CEO Brent Saunders will be responsible for the oversight of all Pfizer ($PFE) and Allergan's combined commercial businesses under the new deal agreement between the two. Release

> Novartis ($NVS) has won European approval for Cosentyx in ankylosing spondylitis and psoriatic arthritis. Report

> AstraZeneca ($AZN) has agreed to sell U.S. rights to Crohn's disease drug Entocort to Perrigo ($PRGO) for $380 million. Release

> Gilead ($GILD) has won a European green light for HIV regimen Genvoya. Release

> Merck ($MRK) has launched antibiotic Zerbaxa in the U.K. More

And Finally... AstraZeneca ($AZN) will sponsor a new health and science education element of U.K. soccer team Cambridge United's school sports program. More

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.

Sanofi and Regeneron's blockbuster Dupixent is eyeing an approval in eosinophilic esophagitis after cutting patients' difficulty breathing.